Skip to main content
OpenTrials
Completed

NCT Number: NCT00729430

Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging

Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the body. This study will evaluate a new MRI technique in people who have recently had a heart attack. Researchers will also examine the effect of fish oil supplementation on heart health in study participants.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Brigham and Women's Hospital, Shapiro Cardiovascular Center

Boston, Massachusetts, 02115, United States

About this study

A new MRI technique to examine the heart was recently developed. In this study, researchers will use this new technique to evaluate the heart in people who have recently had a heart attack to determine whether a specific pattern of heart muscle damage is related to sudden cardiac death. This fatal condition, also known as cardiac arrest, occurs when the heart abruptly stops pumping blood to the body, resulting in loss of consciousness, absence of pulse, and a stop in breathing. The most common cause of sudden cardiac death is a heart attack.

In addition to evaluating the new heart MRI technique, this study will also examine the effects of fish oil supplementation in people who have recently had a heart attack. Recent research has shown that omega-3 fatty acids, commonly found in fish oil, may be beneficial for people with heart conditions. Lastly, the study will determine whether specific biomarkers and genetic factors can help predict the likelihood of a person dying from sudden cardiac death after previously experiencing a heart attack.

Apart from studying the likelihood of sudden cardiac death, This study will measure the change in structure and pumping function of the heart (known as ventricular remodeling) and this study will determine if the high dose of fish oil treatment will result in an improvement of the heart.

This study will enroll people who have had a heart attack in the 2 to 4 weeks before study entry. At a baseline study visit, participants will undergo an MRI of their heart and complete an exercise stress test on a treadmill. A blood sample will be collected, and women will provide a urine sample for a pregnancy test. Questionnaires asking about diet, medical history, and emotions will also be completed. Participants will then be randomly assigned to receive either fish oil supplements or placebo on a daily basis for 6 months. Every 2 to 3 months, study researchers will call participants to check on their health and progress. At a study visit at Month 6, participants will undergo repeat baseline testing. After this visit, study researchers will call participants every 6 months for 3 years to follow up on participants' health status.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Experienced a heart attack in the 2 to 4 weeks before study entry
  • Lives in the greater Boston area or adjacent regions (within a 50-mile radius of Boston)

Exclusion criteria

  • Unable to undergo an MRI because of metallic implants (e.g., pacemakers, an implantable cardioverter defibrillator [AICD]) at time of study entry
  • Active cancer or any other terminal illness with an expected survival rate of less than 6 months after study entry
  • Significant kidney dysfunction with a glomerular filtration rate (GFR) of less than 60 mL/min in the 2 weeks before study entry
  • Inability to follow study procedures
  • Pregnant
  • Hemodynamic instability
  • Urgent clinical need for a pacemaker or AICD
  • Inaccessibility of medical records

Treatment and study plan

Omega-3 Fatty Acids (Fish Oil Supplements)

Drug

4 grams of omega-3 fatty acids taken orally once per day for 6 months

Other names: Lovaza (GlaxoSmithKline)

Placebo

Drug

Placebo tablets taken orally once per day for 6 months

Other names: Corn oil placebo

Primary outcomes

  1. Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling

    Time frame: Before and after study treatments

    Measured as change in left ventricular end-systolic volume indexed to body surface area from baseline to post-treatment (6-months)

Secondary outcomes

  1. Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis

    Time frame: Measured in the 3-year follow-up period after participant's last study visit

    Measured as change in myocardial extracellular volume fraction of non-infarcted myocardium from baseline to post-treatment (6-months)

  2. Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction

    Time frame: Measured in the 3-year follow-up period after participant's last study visit

    Measured as change in left ventricular ejection fraction from baseline to post-treatment (6-months)

  3. Effect of Omega-3 Fatty Acids on Infarct Size

    Time frame: Measured in the 3-year follow-up period after participant's last study visit

    Measured as change in infarct size from baseline to post-treatment (6-months)

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • GlaxoSmithKline
  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Prognostic, Anti-arrhythmic, and Ventricular Remodeling Effects of High Dose Fish Oil in Patients With a Recent Myocardial Infarction

Acronym: OmegaREMODEL

Important dates

Study start
2008
Primary completion
2013
Study completion
2014
First posted
Aug 7, 2008
Registry last updated
Jun 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.